Skip to main content
. Author manuscript; available in PMC: 2022 Mar 9.
Published in final edited form as: J Mol Cell Cardiol. 2021 May 29;158:163–177. doi: 10.1016/j.yjmcc.2021.05.015

Fig. 7.

Fig. 7.

Validation of computational drug screening with human clinical data. (A) Experimentally measured dose dependent inhibition of hERG by sotalol (colored symbols) and model 2 optimization for d-sotalol (solid red line) and for l-sotalol (dashed black line) using data from ref. [80]. See Fig. 6 caption for sources of experimental data. (B) Concentration dependent increase in QT intervals by d,l-sotalol with hERG channel block alone (red circles) compared to clinical data (black diamonds) from ref. [82]. (C) During concurrent ISO 1 μM application to model sympathetic stimulation, model 2 simulations showed a concentration dependent increase in QT interval by d,l-sotalol dependent hERG block and βAR blockade (red asterisks), which compared well to clinical data from ref. [82] (black diamonds).